Thalix
formulated to alleviate symptoms of multiple myeloma to support patient stabilization.
Strengths: 50 · 100mg
Where to Check Availability
Medicine details
- Conditions
- Alternative names
Thalidomide BMS; Thalidomide Celgene
- Therapeutic class
Immunomodulator
- Pharmacological class
Thalidomide analogue
- Minor side effects
somnolence; dizziness; peripheral oedema; constipation
- Moderate side effects
peripheral neuropathy; neutropenia
- Dosage forms
Capsule, hard
- Administration route
Oral use
- Prescription status
POM
- Manufacturer
Natco Pharma
- Onset Time
3–4 hours
- Duration
24 hours
- Storage instructions
Store in a safe location and return unused capsules to the pharmacy.
- Drug interactions
hormonal contraceptives; alcohol; sedatives
- Age restrictions
Not for use in children.
Contraindications
pregnancy; women of childbearing potential unless strict contraceptive measures exist; severe hypersensitivity
Precautions and warnings
requires participation in a mandatory pregnancy prevention programme; monitor for peripheral neuropathy; risk of thrombotic events
Serious side effects
teratogenicity — requires immediate medical attention; venous thromboembolism — requires immediate medical attention
Patient summary
formulated to alleviate symptoms of multiple myeloma to support patient stabilization.
Mechanism of action
The drug exerts immunomodulatory, anti-inflammatory, and anti-angiogenic properties. It alters cytokine production, specifically inhibiting tumour necrosis factor-alpha, and restricts the growth of new blood vessels supplying tumour cells.
Pregnancy and breastfeeding
Pregnancy: Absolute contraindication due to high risk of severe birth defects. Breastfeeding: Not recommended.
Thalix
formulated to alleviate symptoms of multiple myeloma to support patient stabilization.
Editorial Notes
- Active ingredient(s): Thalidomide
- Listed indication(s): Multiple Myeloma
Usually available as
- 60 capsules - 50 mg1460-50-mg-17655
- 30 capsules - 100 mg1460-100-mg-17650